Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC released a 2021 update of its syndicated report on innovation funding schemes in Europe

Innovative payment schemes are an important part of the reimbursement landscape for medical technologies. Two key types of schemes are innovation funding (when payment is provided for innovation unconditionally) and coverage with evidence development (when either financing for a study or coverage with the obligation to perform the study is provided to medical technology).

MTRC has developed an in-depth overview of the innovative payment schemes, active in 2021 in seven European countries, including detailed statistics about the activity of the schemes. This report is built on the 2018 report, sponsored by the Med Tech Europe, but it includes a significant revision of several sections, an update of all statistical information, and several completely new sections (G-BA Innovation Fund in Germany, New subsidy for promising care in the Netherlands, Article 51 of the Social Security Law in France, Med Tech Funding Mandate in England).

A syndicated report (135 pages) reviews details of innovation funding and coverage with evidence development schemes in Europe, including Austria, Belgium, England, France, Germany, the Netherlands, and Switzerland.

For each scheme, information about objective, inclusion criteria, applicant, stakeholders involved, clinical and economic evidence requirements, and statistics (including at least 2019-2020 data; but for most schemes – statistics for multiple years) is included. 

Learn more, obtain sample pages and request a quote here